Models for 10,000 Human Diseases

The promises and problems with ADCs

Antibody drug conjugates (ADCs) are targeted cancer therapies that combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs. In contrast to conventional chemotherapies, which do not discriminate between healthy and cancerous cells, ADCs are designed to deliver cytotoxic drugs directly to tumors and are therefore considered to be a more efficacious and safer therapeutic option. In this article, we comment on the progress as well as the safety and efficacy challenges associated with ADC development. Firstly, how do ADCs work? ADCs (have been)  described as the magic bullets of cancer treatment, because they combine the specific targeting ability of...

Cell of the Month: Liver Sinusoidal Endothelial Cells

Liver sinusoidal endothelial cells (LSECs) are highly specialized liver endothelial cells that form a physical barrier between the blood and hepatocytes. They are the most abundant non-parenchymal hepatic cell population. LSECs play an important role in physiological,...

read more

Tempo-iMG™: Architectural Strategies

Tempo-iMG™ was cited in in a study that investigated HIV-1 integration in the unexplored microglia reservoir that gives rise to continued HIV replication in infected cells. Scientists used Tempo-iMG™ human iPSC-derived microglia to determine that CTCF, an...

read more

Tempo Bioscience Services

Disease Models and Assay Services

Tempo offers services and alliances based on our advanced technological platforms and a range of capabilities. Our team differentiates ourselves based on a strong commitment to innovative solutions and quality R&D for our partners.

Tempo Bioscience Support

On Demand Custom Engineered Cell Models

Tempo develops patient relevant stem cell (iPSCs) based models to support drug discovery, preclinical studies, and early-stage clinical development.